{
    "clinical_study": {
        "@rank": "77432", 
        "brief_summary": {
            "textblock": "This study will investigate the use of sertraline (Zoloft) to decrease alcohol consumption\n      and crime-related post-traumatic stress disorder in those individuals with both disorders.\n      This will be a 12-week, placebo-controlled, double-blind outpatient trial.\n\n      All subjects will receive cognitive behavioral therapy in addition to a placebo or\n      sertraline.  Comprehensive evaluation will be done at study entry; treatment termination;\n      and 6, 9, and 12 months after study entry."
        }, 
        "brief_title": "Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder", 
        "completion_date": "December 2000", 
        "condition": [
            "Alcoholism", 
            "Post-Traumatic Stress Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alcoholism", 
                "Stress Disorders, Post-Traumatic", 
                "Stress Disorders, Traumatic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets criteria for alcohol abuse or dependence and post-traumatic stress disorder.\n\n          -  Laboratory tests for blood and urinalysis must be within normal limits.\n\n          -  Must be clearly motivated to obtain benefit from treatment and keep appointments for\n             study visits and therapy sessions.\n\n          -  Females who use an acceptable method of birth control, are sterilized, or are at\n             least 2 years post-menopausal.\n\n        Exclusion Criteria:\n\n          -  Have a diagnosis of schizophrenia, bipolar affective disorder, dissociative identity\n             disorder, eating disorder, substance dependence in the last 60 days.\n\n          -  Currently suicidal.\n\n          -  Medical reasons not to receive drug therapy.\n\n          -  Allergy or hypersensitivity to selective serotonin inhibitor antidepressants.\n\n          -  Significant hematological, endocrine, cardiovascular, renal, hepatic, neurological,\n             or gastrointestinal disease.\n\n          -  Liver function test greater than 2 times the normal level\n\n          -  Require ongoing therapy with another psychoactive drug during the study period.\n\n          -  Females who are pregnant or lactating."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000446", 
            "org_study_id": "NIAAABRA10761"
        }, 
        "intervention": {
            "intervention_name": "sertraline (Zoloft)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sertraline"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Charleston", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29425"
                }, 
                "name": "Department of Psychiatry and Behavioral Science, Medical University of South Carolina"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Sertraline Treatment in Comorbid Post-Traumatic Stress Disorder and Alcoholism", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000446"
        }, 
        "source": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2004"
    }, 
    "geocoordinates": {
        "Department of Psychiatry and Behavioral Science, Medical University of South Carolina": "32.777 -79.931"
    }
}